- Home
- MSGS vs ABVX Comparison
MSGS vs ABVX Comparison
Compare MSGS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSGS
- ABVX
- Stock Information
- Founded
- MSGS 1879
- ABVX 2013
- Country
- MSGS United States
- ABVX France
- Employees
- MSGS N/A
- ABVX N/A
- Industry
- MSGS Services-Misc. Amusement & Recreation
- ABVX
- Sector
- MSGS Consumer Discretionary
- ABVX
- Exchange
- MSGS Nasdaq
- ABVX Nasdaq
- Market Cap
- MSGS 4.9B
- ABVX 5.3B
- IPO Year
- MSGS N/A
- ABVX N/A
- Fundamental
- Price
- MSGS $219.67
- ABVX $81.00
- Analyst Decision
- MSGS Buy
- ABVX Strong Buy
- Analyst Count
- MSGS 6
- ABVX 8
- Target Price
- MSGS $258.83
- ABVX $90.63
- AVG Volume (30 Days)
- MSGS 182.2K
- ABVX 1.2M
- Earning Date
- MSGS 10-31-2025
- ABVX 08-11-2025
- Dividend Yield
- MSGS N/A
- ABVX N/A
- EPS Growth
- MSGS N/A
- ABVX N/A
- EPS
- MSGS N/A
- ABVX N/A
- Revenue
- MSGS $1,039,220,000.00
- ABVX $7,073,400.00
- Revenue This Year
- MSGS N/A
- ABVX $25.23
- Revenue Next Year
- MSGS $4.90
- ABVX N/A
- P/E Ratio
- MSGS N/A
- ABVX N/A
- Revenue Growth
- MSGS 1.18
- ABVX N/A
- 52 Week Low
- MSGS $173.26
- ABVX $4.77
- 52 Week High
- MSGS $237.99
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- MSGS 75.14
- ABVX 57.75
- Support Level
- MSGS $209.11
- ABVX $82.72
- Resistance Level
- MSGS $216.24
- ABVX $86.72
- Average True Range (ATR)
- MSGS 4.35
- ABVX 3.92
- MACD
- MSGS 2.28
- ABVX -1.82
- Stochastic Oscillator
- MSGS 100.00
- ABVX 20.12
About MSGS Madison Square Garden Sports Corp. (New)
Madison Square Garden Sports Corp owns and operates a portfolio of assets featuring some of the recognized sports teams, including the Knicks of the NBA and the Rangers of the NHL. It generates revenue from several sources: ticket sales and a portion of suite rental fees at The Garden and others. It has one operating and reportable segment and one reporting unit for goodwill impairment testing purposes.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.